Business
Capricor Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 15, 2025 Deadline to file Lead Plaintiff Motion
Investors can contact the law firm at no cost to learn more about recovering their lo...
About this update from Caprock Mining Corp
[{"type":"text","content":"Capricor Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 15, 2025 Deadline to file Lead Plaintiff Motion\n\n\n\n\n Investors can\n \n\n\n contact\n \n\n\n the law firm at no cost to learn more about recovering their losses\n \n\n\n LOS ANGELES, Sept. 09, 2025 (GLOBE NEWSWIRE) --\n \n The Portnoy Law Firm\n \n advises\n \n Capricor Therapeutics, Inc.\n \n (\"Capricor\" or the \"Company\") (NASDAQ: CAPR) investors of a class action representing investors that bought securities between\n \n October 9, 2024 and July 10, 2025\n \n , inclusive (the \"Class Period\"). Capricor investors have until\n \n September 15, 2025\n \n\n to file a lead plaintiff motion.\n \n\n\n Investors are encouraged to contact attorney\n \n Lesley F. Portnoy\n \n , by phone 310-692-8883 or\n \n email\n \n : [email protected], to discuss their legal rights, or\n \n click here\n \n to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.\n \n\n\n CASE ALLEGATIONS:\n \n Capricor is a clinical-stage biotechnology company developing transformative cell- and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”) and other diseases.\n \n\n The Capricor class action lawsuit alleges that throughout the Class Period, defendants made false or misleading statements and/or failed to disclose adverse facts concerning four-year safety and efficacy data from its Phase 2 HOPE-2 trial, giving the false impression that Capricor could obtain first approval for DMD cardiomyopathy.\n \n\n The complaint further alleges that on May 5, 2025, Capricor announced it had completed its mid-cycle review meeting with the U.S. Food and Drug Administration (“FDA”) for deramiocel, reporting no significant deficiencies and confirming that the application remained on track for a Prescription Drug User Fee Act action date of August 31, 2025. The FDA also confirmed its intent to hold an advisory committee meeting. According to the complaint, on this news, Capricor’s stock fell more than 29%.\n \n\n The Capricor class action lawsuit further alleges that on June 20, 2025, Stat News reported that Vinjay Prasad, director of the FDA’s Center for Biologics Evaluation and Re...